ZUG

楚格

, Switzerland and BOSTON,

瑞士和波士顿，

June 30, 2025

2025年6月30日

(GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named to the fifth annual

(GLOBE NEWSWIRE) -- CRISPR Therapeutics（纳斯达克股票代码：CRSP），一家专注于为严重疾病开发基于基因的变革性药物的生物制药公司，被评为第五届年度

TIME 100 Most Influential Companies

全球百大最具影响力公司

list. The Company was recognized in the Pioneers category for its groundbreaking work in advancing the field of gene editing.

名单。该公司因其在推进基因编辑领域的开创性工作而在“先锋”类别中获得认可。

TIME highlighted CRISPR Therapeutics’ expansion beyond its landmark success in treating sickle cell disease and beta thalassemia, noting the Company’s progress into diseases with significant unmet medical need such as cardiovascular and autoimmune diseases. This momentum reflects CRISPR Therapeutics’ broader vision to make genetic medicine more scalable and accessible for patients worldwide..

《时代》杂志强调了CRISPR Therapeutics公司超越其在治疗镰状细胞病和β地中海贫血方面的里程碑式成功，指出该公司在心血管疾病和自身免疫疾病等具有重大未满足医疗需求的领域中取得的进展。这一势头反映了CRISPR Therapeutics更广泛的愿景，即让基因药物更具可扩展性，并为全球患者提供更广泛的获取途径。

“Since our founding,

“自我们成立以来，

CRISPR Therapeutics

CRISPR治疗公司

has been driven by a mission to transform medicine through bold science and meaningful innovation,” said

一直以通过大胆的科学和有意义的创新来变革医学为使命，”他表示。

Samarth Kulkarni

萨马尔·库尔卡尼

, Ph.D., Chairman and Chief Executive Officer of

，博士，董事长兼首席执行官

CRISPR Therapeutics

CRISPR治疗公司

. “We are honored to be recognized by TIME. This acknowledgement is testament to the extraordinary dedication and collaboration across our teams to pioneer the next frontier of genetic medicine and improve the lives of patients around the world.”

“我们很荣幸得到《时代》杂志的认可。这一肯定证明了我们团队在开拓基因医学的下一个前沿领域和改善世界各地患者生活方面所展现出的非凡奉献精神和协作精神。”

To select the list of the world's most influential businesses of the year, TIME editors requested nominations across sectors, surveyed its global network of contributors and correspondents around the world, and sought advice from outside experts. They evaluated each company on key factors, including impact, innovation, ambition, and success.

为了选出年度全球最具影响力的公司名单，《时代》杂志的编辑们跨行业征集提名，调查了其遍布全球的撰稿人和记者网络，并寻求了外部专家的建议。他们根据影响力、创新性、雄心和成功等关键因素对每家公司进行了评估。

The result is a diverse group of organizations shaping the future of business and society..

结果是形成了一个多样化的组织群体，塑造着商业和社会的未来。

About CRISPR Therapeutics

关于CRISPR Therapeutics

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases.

自十多年前成立以来，CRISPR Therapeutics已从一家推进基因编辑项目的研究型公司发展成为引领者，并成功庆祝了首个基于CRISPR疗法的历史性获批。该公司在包括血红蛋白病、肿瘤学、再生医学、心血管、自身免疫和罕见疾病在内的广泛疾病领域拥有多样化的产品候选组合。

In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY.

2018年，CRISPR Therapeutics将首个CRISPR/Cas9基因编辑疗法推进到临床，以研究镰状细胞病和依赖输血的β地中海贫血的治疗。从2023年底开始，CASGEVY。

®

®

(exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines.

(exagamglogene autotemcel [exa-cel]) 已在多个国家获批用于治疗符合条件的患者。荣获诺贝尔奖的CRISPR技术已经彻底改变了生物医学研究，并代表了一种强大的、经过临床验证的方法，有潜力创造一类可能具有变革性的新药物。

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

为了加速和扩大其努力，CRISPR Therapeutics 已与包括 Vertex Pharmaceuticals 在内的领先公司建立了战略合作伙伴关系。CRISPR Therapeutics AG 总部位于瑞士楚格，其全资美国子公司 CRISPR Therapeutics, Inc. 以及研发业务基地分别位于马萨诸塞州波士顿和加利福尼亚州旧金山。

To learn more, visit .

要了解更多信息，请访问。

www.crisprtx.com

www.crisprtx.com

.

。

Investor Contact:

投资者联系方式：

+1-617-307-7503

+1-617-307-7503

ir@crisprtx.com

投资者关系@CRISPR疗法.com

Media Contact:

媒体联系人：

+1-617-315-4493

+1-617-315-4493

media@crisprtx.com

media@crisprtx.com

Source: CRISPR Therapeutics AG

来源：CRISPR Therapeutics AG